MARKET

ALVR

ALVR

Allovir, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.34
+0.15
+0.57%
Opening 12:06 10/30 EDT
OPEN
26.25
PREV CLOSE
26.19
HIGH
26.34
LOW
24.73
VOLUME
45.21K
TURNOVER
--
52 WEEK HIGH
45.28
52 WEEK LOW
18.15
MARKET CAP
1.61B
P/E (TTM)
-59.4314
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Could The AlloVir, Inc. (NASDAQ:ALVR) Ownership Structure Tell Us Something Useful?
Every investor in AlloVir, Inc. (NASDAQ:ALVR) should be aware of the most powerful shareholder groups. Generally...
Simply Wall St. · 4h ago
Data to Be Presented at IDWeek 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral InfectionsCAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that
GlobeNewswire · 10/21 12:30
AlloVir Gains 14% On FDA Trial Nod For Covid-19 Therapy
Shares of AlloVir jumped 13.6% on Friday after the US Food and Drug Administration (FDA) granted clinical trial approval for its ALVR109, an allogeneic, off-the-shelf virus-specific T cell Covid-19 therapy against SARS-CoV-2. The therapy is being designed and developed to halt the progression of COVID
SmarterAnalyst · 09/21 10:14
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
AlloVir gets green signal to initiate clinical trial for ALVR109 in COVID-19
The FDA has signed off AlloVir's ([[ALVR]] +6.0%) Investigational New Drug application ((IND)) for ALVR109, an allogeneic, off-the-shelf virus-specific T cell therapy candidate against SARS-CoV-2.In March, the company expanded its research collaboration
Seekingalpha · 09/17 14:38
AlloVir Announces FDA Clearance of Investigational New Drug Application For ALVR109 For Treatment Of High-Risk Coronavirus Patients; Proof-Of-Concept Clinical Trial To Begin Q4 2020
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients - ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy
Benzinga · 09/17 14:06
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
\- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients\- Proof-of-concept clinical trial with ALVR109 to begin in Q42020CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late
GlobeNewswire · 09/17 13:49
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept TrialsCAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the
GlobeNewswire · 09/08 21:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALVR. Analyze the recent business situations of Allovir, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALVR stock price target is 46.50 with a high estimate of 52.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 4
Institutional Holdings: 100.14K
% Owned: 0.16%
Shares Outstanding: 61.17M
TypeInstitutionsShares
Increased
0
0
New
4
100.14K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALVR
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Allovir Inc stock information, including NASDAQ:ALVR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALVR stock methods without spending real money on the virtual paper trading platform.